Brussels, 10 June 2025

EuropaBio welcomes the Commission’s commitment to a bold EU Biotech Act and its acknowledgement of biotech industries as key drivers for the Union’s competitiveness and security.

The Biotech Act must maximise Europe’s global impact and strategic leadership in biotech and biomanufacturing, whilst enhancing competitiveness and economic security. This can be achieved through faster financing to power the next generation of breakthrough biotech, simpler legislation to unlock innovation at scale and strengthening regional resilience and attractiveness throughout the global value chain.

EuropaBio is also calling for biotechnology to be strongly recognised within an ambitious Omnibus Package to urgently address current hurdles with existing legislation, enabling the sector to be more competitive globally and to ensure that biotech products are manufactured in Europe.

Dr Claire Skentelbery, Director General of EuropaBio, commented, “The EU Biotech Act must fully deliver on Europe’s biotech capacity, through emerging innovations translated into scaled and competitive companies here and attracting global investment for European resilience and a thriving market.”

EuropaBio looks forward to engaging with stakeholders to shape a bold and impactful Act as part of a broader legislative cluster supporting the integration and impact of biotechnology.